Compare XPL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | ICCC |
|---|---|---|
| Founded | 1984 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6M | 55.5M |
| IPO Year | N/A | 1987 |
| Metric | XPL | ICCC |
|---|---|---|
| Price | $0.74 | $6.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.20 | N/A |
| AVG Volume (30 Days) | ★ 228.6K | 37.3K |
| Earning Date | 10-31-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $25.64 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $0.54 | $4.28 |
| 52 Week High | $0.90 | $7.60 |
| Indicator | XPL | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.61 |
| Support Level | N/A | $6.15 |
| Resistance Level | N/A | $6.89 |
| Average True Range (ATR) | 0.00 | 0.37 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 64.39 |
Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.